EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
4 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| sildenafil citrate EU/3/23/2831 14 clinical trials → |
Treatment of Leigh syndrome | Active (positive) | 13 Oct 2023 |
| sildenafil EU/3/17/1885 14 clinical trials → |
Treatment of congenital diaphragmatic hernia | Active (positive) | 20 Jun 2017 |
| sildenafil citrate EU/3/10/815 14 clinical trials → |
treatment of postcardiotomy right ventricular failure | Active (positive) | 26 Nov 2010 |
| sildenafil citrate EU/3/03/178 14 clinical trials → |
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension | Expired | 12 Dec 2003 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 11 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.